Switching to ustekinumab for kids with Crohn's or ulcerative colitis who developed psoriasis after anti-TNF therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study focuses on pediatric patients with Crohn's disease or ulcerative colitis who have stopped an anti-TNF medication due to a paradoxical psoriasiform skin eruption. Eligible participants are under 19, have confirmed IBD, and have used an anti-TNF for at least three months with a dermatologist-confirmed severe psoriasis resistant to standard treatments. The intervention involves switching from the anti-TNF agent to ustekinumab and observing the effects on IBD symptoms and skin findings. The trial is conducted at CHU de Nice in Nice, France, led by Centre Hospitalier Universitaire de Nice, with no listed collaborators. Primary endpoints are not specified in the provided description, but the focus is on safety and clinical response after switching therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients capable of giving their non-opposition
2. Patient \<19 years
3. Diagnosis of IBD established
4. Having received an anti-TNFα for IBD for at least 3 months
5. Having stopped the anti-TNFα for a severe paradoxical psoriasis resistant to usual treatments (topical or systemic) diagnosed by a dermatologist
6. Having received Ustekinumab in relay of the anti-TNFα

Exclusion Criteria:

1. Patient \> 18 years
2. Diagnosis of IBD not confirmed
3. Discontinuation of anti-TNFα for a cause other than psoriasis

Where it's running

• CHU de Nice
  Nice, France, France Recruiting

Study contacts

• Principal investigator: Christine CHIAVERINI — Centre Hospitalier Universitaire de Nice
• Study coordinator: Christine Chiaverini, Dr
• Email: chiaverini.c@chu-nice.fr
• Phone: 04 92 03 47 02

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• Guselkumab for adults with Crohn's disease after ustekinumab failure

  This study will try guselkumab for adults with moderate to severe Crohn's disease who did not respond to or could not tolerate ustekinumab to see if they reach remission after 52 weeks.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07487480

• Guselkumab vs Ustekinumab for stricturing Crohn's disease

  This study will follow adults with moderate-to-severe Crohn's disease and confirmed intestinal strictures to see if treatment with guselkumab or ustekinumab better controls obstructive symptoms and disease activity.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07444060

• Guselkumab for Chinese patients with Crohn's disease who stopped responding to ustekinumab

  This study tests whether guselkumab can help Chinese patients with active Crohn's disease who initially responded to ustekinumab but later lost response.

  Recruiting at 5 sites Phase 4 Xian-Janssen Pharmaceutical Ltd. · Guangzhou and 4 other locations · NCT07310095

• Reducing ustekinumab dosing for Crohn's disease and ulcerative colitis

  This will try giving ustekinumab less often—changing from every 4 or 8 weeks to every 8 or 12 weeks—to see if people with Crohn's disease or ulcerative colitis in deep remission can stay well.

  Recruiting Phase 4 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT07303686

• Switching to guselkumab for adults with active IBD after ustekinumab

  We will try guselkumab (Tremfya) in adults with active IBD whose symptoms didn't improve enough on ustekinumab.

  Recruiting at 12 sites TIDHI Innovation Inc. · Calgary, Alberta and 13 other locations · NCT07245394

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.